PTC Therapeutics PTCT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from PTC Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's EBITDA margin?
- PTC Therapeutics (PTCT) reported EBITDA margin of 7.3% in Q1 2026.
- How has PTC Therapeutics's EBITDA margin changed year-over-year?
- PTC Therapeutics's EBITDA margin decreased by 82.6% year-over-year, from 41.8% to 7.3%.
- What is the long-term trend for PTC Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), PTC Therapeutics's EBITDA margin has grown at a -11.2% compound annual growth rate (CAGR), from -102% to 56.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.